EyePoint Pharmaceuticals' stock dropped sharply after its wet AMD drug DURAVYU missed the primary trial endpoint, though an adjusted analysis showed it matched the standard treatment and cut treatment burden by 42%. Despite the setback, a Jefferies analyst set a price target of $8.00, implying a 73.72% upside from the current price of around $4.61. The stock's decline reflects investor caution, but the analyst's positive outlook highlights potential value in the drug's secondary benefits and future market prospects. EyePoint's market cap is now about $382 million, with high trading volume signaling active investor interest.
Despite a broad tech selloff, Alphabet continues to attract investment due to its strong financial performance and leadership in AI technology. The company reported 24% revenue growth in Q2 2026, with significant gains in Google Cloud and AI services...
Ethereum (ETH) has surged from below $2,400 to above $2,550, clearing a key resistance zone and now testing the $2,650–$2,700 range. This breakout is supported by renewed institutional demand, including positive inflows into U.S. spot Ethereum ETFs a...
Cardano has been integrated into the x402 SDK, allowing apps and AI agents to make payments using ADA and Cardano Native Tokens (CNTs) without needing accounts or API keys. This development opens up Cardano for seamless use across hundreds of platfor...
Galleon Gold has begun underground development at its West Cache Gold Project in Timmins, Ontario, marking a key step in its plan to extract an 86,500-tonne bulk sample. The company completed surface preparations and is now advancing ramp development...
Bitcoin's price on Bitfinex briefly surged to nearly $155,000 due to a split-second liquidity shortage and forced liquidations in the BTC-PERP futures market, while the spot price remained stable around $85,000. This glitch caused a short-term price ...
